A recent study reveals that patients who discontinue blockbuster GLP-1 drugs like Wegovy and Mounjaro tend to recover reduced body mass far faster than those who stop conventional diet and exercise programs.
Published data in a major health publication shows that while overweight people frequently drop substantial amounts of their total mass while undergoing treatment, the mass is regained at an average rate of 0.8 kg per month upon discontinuation.
"Individuals using these treatments need to be cognizant of the danger of quick weight regain when the medication is stopped," warns lead investigator Dr. Susan Jebb.
That rate of regain implies a return to pre-treatment mass in about one and a half years.
Weighing Approaches
The research, which examined dozens of studies involving thousands of participants, contrasted the outcomes of the injectable medications with other pills.
The team emphasize that individuals who lose weight through dieting usually see a more gradual weight regain—around 100 grams monthly—after stopping.
Understanding the Quick Regain
Experts believe the way of the jabs explains the heightened rebound.
These medications copy a natural hormone called glucagon-like peptide-1, which controls appetite.
"Sustained high doses of the hormone concentrations far above than normal might result in the body to produce less of its endogenous hormone, and could diminish sensitivity to its effects," noted Dr. Adam Collins, a dietetics expert.
"Stopping of this hormone supplement results in appetite is uncontrolled, making binge eating much more probable."
A Lifelong Issue?
The NHS recommend the injections for people with weight-linked medical conditions, alongside prescribed diet and exercise modifications.
Professionals argue that, considering the significant potential of relapse, the therapy should be considered life-long.
This perspective is reinforced by drug manufacturers, who note that the results "underscore the persistent nature of obesity," similar to managing diseases like diabetes.
User Testimonies
Users who have come off the jabs report a intense resurgence of hunger.
"I experienced a trigger flipping and you become starving," described one woman.
The struggle is worsened if patients have not developed sustainable dietary or behavioural changes during therapy.
Significant Interest
Figures suggest that millions of people in the UK have used weight-loss jabs in the past year, with desire continuing to grow.
- Adoption is higher among females than males.
- The middle-aged demographic shows the highest usage rates.
- A large proportion access the drugs through private healthcare rather than the NHS.
Finally, experts stress that while GLP-1 drugs are potent agents for shedding pounds, they are not a magic solution and lasting health benefits likely depends on ongoing behavioural support.
